Le Lézard
Classified in: Health, Business

First Light Diagnostics Closes $8.25 Million Series A-2 Financing


CHELMSFORD, Mass., Jan. 16, 2019 /PRNewswire/ -- First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced it has closed an oversubscribed $8.25 million Series A-2 financing.

The financing includes new investment partners from Think.Health Ventures, 10x Group, and Beacon Angels, along with numerous new individual investors and continued participation from current shareholders, such as; LRV Health and Life Science Angels.

"We are excited to have reached this financing milestone," said David Macdonald, CEO of First Light Diagnostics. "The additional capital and strengthening of our investor syndicate will augment our government grants and contracts and allows our team of industry experts to focus on execution of our commercial plans."

The new funding will be used to continue development of the MultiPathtm technology to rapidly detect hospital infections and determine their susceptibility to specific antibiotics. This includes preparation and support for product commercialization and launch in early 2020.

"First Light Diagnostics has developed a compelling solution to address hospital-acquired infections and antibiotic resistance," said Florian Kainzinger of Think.Health Ventures. "The company's unique application of technology and domain expertise with this challenging problem creates an exciting opportunity. We are pleased to partner with First Light as they move to the next phase of their development and commercial product launch."

About First Light Diagnostics

First Light Diagnostics is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and combating the spread of antibiotic resistance. Don Straus is the company's Founder and primary inventor of the company's core scientific technology. Based on its proprietary MultiPathtm detection technology, First Light's products combine the clinical performance of the most advanced commercial laboratory tests with speed, cost-effectiveness, and ease-of-use. The tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy. This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics. To learn more, please visit: www.firstlightdx.com

David Macdonald
President and CEO
First Light Diagnostics
[email protected]
Mobile: (858) 997-9641

SOURCE First Light Diagnostics


These press releases may also interest you

at 07:15
St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that a research team from St. Michael's Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...

at 07:10
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two...

at 07:10
Curida, Small Molecules and Biologics CDMO, Secures Private Equity Investment from Signet Healthcare Partners
Curida Holding AS ("Curida") has announced a significant growth investment from Signet Healthcare Partners ("Signet"), a New York-based healthcare private equity firm. This strategic partnership will enable Curida to accelerate its expansion plans,...

at 07:10
Orthofix Names Andres Cedron as New Chief Legal Officer
Orthofix Medical Inc. , a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer. Cedron most recently served as Vice President and Corporate Secretary at Stryker Corporation,...

at 07:10
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b...

at 07:10
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
United Therapeutics Corporation , a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May...

More news about Health...


News published on and distributed by: